

**REFERENCES**

Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. *Cancer Cell*. 2007 Jul;12(1):9-22.

Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. *Nat Rev Drug Discov*. 2006 Aug;5(8):671-88.

Sabatini DM. mTOR and cancer: insights into a complex relationship. *Nat Rev Cancer*. 2006 Sep;6(9):729-34.

Tanaka C, O'Reilly T, Kovarik JM, Shand N, Hazell K, Judson I, Raymond E, Zumstein-Mecker S, Stephan C, Boulay A, Hattenberger M, Thomas G, Lane HA. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. *J Clin Oncol*. 2008 Apr 1; 26(10): 1596-602.

Albanell J, Dalmases A, Rovira A, Rojo F. mTOR signalling in human cancer. *Clin Transl Oncol*. 2007 Aug;9(8):484-93.

Fan QW, Cheng CK, Nicolaidis TP, Hackett CS, Knight ZA, Shokat KM, Weiss WA. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. *Cancer Res*. 2007 Sep 1;67(17):7960-5.

Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D, Shokat KM, Weiss WA. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. *Cancer Cell*. 2006 May;9(5):341-9.

Rosen N, She QB. AKT and cancer--is it all mTOR? *Cancer Cell*. 2006 Oct;10(4):254-6.

O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. *Cancer Res*. 2006 Feb 1;66(3):1500-8.

**FOR MORE INFORMATION, PLEASE CONTACT:****Paul Resnick, MD, MBA**

Vice President of Business Development  
paul@intellikine.com  
(858) 768-6527

**Christian Rommel, PhD**

Chief Scientific Officer  
christian@intellikine.com  
(858) 768-6503